Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Patent
1997-04-08
1999-06-15
Saunders, David
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
435374, 435378, 435397, 435402, 435405, 435408, 4353071, 4353081, 604408, C12N 1563, C12N 508, C12N 510, A61J 110
Patent
active
059121777
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a system for selectively immobilizing stem cells, for example those from the haematopoietic progenitor compartment (HPC). This allows stem cells to be selectively harvested free of other cell types, whereby the harvested cells may be cultured or otherwise manipulated.
BACKGROUND
Stem cells are primitive cells which are capable of self-renewal, and ultimately become differentiated into specific cell types of defined function. Stem cells are capable of proliferation either to generate further identical stem cells, or to produce more differentiated cell types. Later more differentiated cell types always become more differentiated on proliferation. Stem cells exist for most tissue types but are continuously active in the skin and mucosal systems, and for the blood and bone marrow (haematopoietic stem cells).
Haematopoietic stem cells are capable of self-renewal, multilineage proliferation and differentiation, and long-term support of the haematopoietic and lymphoid systems. They form a subpopulation within the Haematopoietic progenitor compartment (HPC), which mainly comprises cells of more limited potentiality. HPC cells are mainly located within the bone marrow stroma, where complex interaction with stromal cells, extracellular matrix components and cytokines, permits regulation of cell proliferation and differentiation. HPC cells are also present in the blood under a variety of physiological, pathological and iatrogenic circumstances. HPC can be harvested from bone marrow or peripheral blood, and will re-engraft the bone marrow following intravenous infusion in patients who have received ablative (i.e. destructive) doses of chemotherapy and/or radiotherapy, leading to regeneration of haematopoiesis and immunity. Thus, HPC cell transplantation is of considerable clinical utility in the management of patients with haematological and solid malignancies, bone marrow failure, and inborn errors of haematopoiesis, immunity or metabolism.
There is thus a need for supplies of autologous HPC cells which may be cultured in vitro prior to reintroduction into a patient whose HPC cell population has been depleted due to chemotherapy and/or radiotherapy. The populations of such HPC cells may take many weeks or months to recover naturally to their normal levels. The use of autologous cells from the patient himself avoids rejection of the transplanted cells. An object of the present invention is to address the culturing of such HPC cells in a convenient manner. This is carried out with a view to improving the rate and durability of haematopoietic recovery, the removal of any neoplastic contamination, and the possible use of HPC calls as a vehicle for immunotherapy and gene therapy.
In vivo, HPC cells are generally located within the bone marrow stroma. In vitro, HPC cells are able to adhere to bone marrow stromal layers before proliferating and releasing more committed progenitors. Stem cells undergo marked proliferation and differention into multiple lineages, ultimately giving rise to fully differentiated cells, such as red blood cells, platelets, a variety of white blood cells, and also immune cells such as T lymphocytes and B lymphocytes. Thus, the reintroduction of HPC cells or stem cells into the patient who is depleted therein, allows efficient repopulation of these haematopoietic cell types.
Although stromal layers may provide a suitable substrate for HPC cell immobilization and culture, such stromal layers have a number of disadvantages. Firstly they are fragile. This imposes limitations on the types of systems which may be employed to culture such cells. The growth of HPC cells in vitro requires a rigid substrate on which the layers of stromal cells can be grown in order to maintain the integrity of the stroma. Moreover, it is found that HPC cells grown on stroma in this way only have a limited storage lifetime, of about six to eight weeks due to death of the stromal cells. A further problem is that the use of the stromal cells for the growth of HPC cells is lim
REFERENCES:
Weinstein, R et al. Blood. 73(1): 111-116, Jan. 1989.
Long, MW and Dixit, VM et al. Blood. 75(12): 2311-2318, Jun. 15, 1990.
Long, MW et al. J. Clin Invest. 90: 251-255, Jul. 1992.
Hosokawa, T e tal. Oncology Research. 5(4-5): 183-189, Apr. 1993.
Sekhsaria, S et al. Proc. Nat. Acad. Sci. (USA). 90(16): 7446-7450, Aug. 15, 1993.
Lemoli, RM et al. Exp. Hematology. 20(5): 569-575, Jun. 1992.
Lebkowski, JS et al. Transplantation. 53(5): 1011-1019, May 1992.
Stephen G. Emerson; "The Stem Cell Model of Hermatppoiesis", In Hoffman, R., Benz, EJ, Shattil SJ, Fune, B., Cohen, HJ (Eds); Haematology. Basic Principles and Practice: Churchill Living, NY (1991); pp. 72-81.
Murphy William Gerrard
Turner Marc Leighton
Common Services Agency
Saunders David
VanderVegt F. Pierre
LandOfFree
Stem cell immobilization does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stem cell immobilization, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stem cell immobilization will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-402161